Professional Documents
Culture Documents
ACKNOWLEDGEMENTS
The 2017 Edition of the Drug Price Reference Index (DPRI) is a fruit of hard work, dedication and team efforts
of the Department of Health (DOH) Pharmaceutical Division’s System Support Unit supervised by Ms. Vanessa J. Saulog
– Obera, together with her team members namely: Mr. Achilles V. Aragona who also prepared the cover design and
layout of the booklet, Ms. Priscilla Margarette H. Alimario, Mr. John Lester M. Custodio, Ms. Geny C. Belmonte, Mr.
Christian M. Villostas and their team leader Mr. Jeffrey T. Castro;
The Electronic Drug Price Monitoring System (EDPMS) team for providing market intelligence led by Mr. Patrick
D. Acuna, and his team members: Ms. Grace N. Lagunzad, and Ms. Arlyn A. Rabi;
Mr. Aris Posadas for continuously enhancing the DPRI website and database;
To all NDP Compliance Officers and EDPMS Helpdesks who aid in the implementation of the DPRI and to the
DOH-Pharmaceutical Division family with our OIC-Chief Irene V. Florentino-Farinas for their support;
All DOH Retained / Specialty Hospitals and Regional Offices for contributing their data to the Department of
Health;
The Drug Price and Access Advisory Committee (DPAAC) who provided recommendations for the improvement
of the policy headed by Governor Roberto Pagdanganan as Chairman, Dr. Alvin Caballes as Vice-chairman, and the
members of the committee: Dr. Michael Abrigo, Dr. John Wong and Mr. Oscar Picazo;
We also recognize and thank our Health Secretary Francisco T. Duque and former Health Secretary Dr. Paulyn
Jean B. Rosell – Ubial, and OIC – Assistant Secretary Enrique A. Tayag for their unwavering support and commitment
to enforce the DPRI in the government.
Manila, Philippines
18 December 2017
The high and extremely variable prices of medicines in the Philippines impact on access to effective, efficient and
equitable health care. In 2009, a study conducted by Health Action International revealed that there was extreme
variability in the procurement prices of essential medicines across the national and local public health facilities in the
country. On average, originator brands and generic equivalents were procured almost 16 times and 3 times higher,
respectively, compared to prices available on the international market.1
The DOH-Central Bids and Awards Committee (DOH-COBAC) and DOH Hospitals were shown to have more efficient
procurement prices compared to provincial and municipal health facilities, thus leading to variability in access to
essential medicines across the Philippines.
Republic Act (RA) 9502 or the Universally Accessible Cheaper and Quality Medicines Act of 2008 gave the DOH
instruments to monitor and regulate the prices of drugs and medicines to protect consumers and the public procuring
entities from excessive mark-ups applied to prices of medicines resulting from information asymmetry and the lack of
effective market competition.
To address these issues, the DOH Pharmaceutical Division (formerly NCPAM) established a Drug Price Reference Index
(DPRI) for all essential medicines to guide all national and local government health facilities in the efficient sourcing of
pharmaceutical products in the public sector.
The DPRI lists the ceiling prices of essential medicines for government bidding and procurement set by the DOH for all
National and Local Government Health Facilities and Government Agencies. Winning bid prices of essential medicines
within the DPRI ceiling reflect efficient and effective procurement in the government. Their transparency and
enforcement ensure consumer access to medicines and protection from excessive price mark-ups on medicines.
The DPRI only reflects the acquisition costs including landed cost, packaging, drug content, quality assurance,
manufacturing overheads and Food and Drug Administration (FDA) fees. The DPRI excludes other costs such as
pharmacy services, preparation and storage fees, and other reasonable pharmacy mark-ups, which are now being
evaluated by the DOH.
The DPRI aims to improve the efficiency and good governance in the pricing and procurement of medicines in the
public sector through establishing a transparent and publicly available reference price for affordable and quality
medicines. It also aims to guide the Philippine Health Insurance Corporation (PHIC) in setting reimbursement caps for
medicines both for inpatient and outpatient services.
All government entities should be guided by the DPRI when procuring medicines. It shall be applied to all forms of
procurement such as public bidding, direct contracting, shopping, negotiated procurement, emergency procurement
and consignment to ensure that the government achieves the best value for money in sourcing essential medicines.
___________________________________
1
Douglas B, Tisocki K (2009) Public Procurement Prices of Medicines in the Philippines. Health Action International.
In general, the DPRI is calculated based on the prevailing market price collected by the DOH through the Electronic
Drug Price Monitoring System (EDPMS) from different drug establishments which includes, Drug Stores, Drug Chains,
Private Hospital Pharmacy and Government Hospital Pharmacy nationwide.
The reference price is set at the Median or the 50th percentile across the range of prevailing market prices of essential
medicines for each preparation and strength but further reducing the value by 30% to offset the estimated average
retail mark-up. However, prices of innovator products included in the data set are excluded in the calculation except
for those cases wherein the innovator products comprises at least 70% of the total data set
The DPRI is updated annually. All DOH hospitals and ROs submits a copy of their latest purchase orders to the DOH
Pharmaceutical Division. Price data uploaded by all drug establishment nationwide is extracted and analyzed together
with the procurement gathered from DOH facilities. The updated DPRI is based on the current retail price data of
medicines.
For some medicines not listed in this edition, the method on setting the ABC shall depend on the discretion of the
procuring entity (e.g. review of historical awarded price, market survey, MIMS).
All procuring entities are advised to submit the list of medicines that resulted to bid failure at DOH-PD. The report
should comply the template provided by DOH-PD that can be downloaded at their website at www.dpri.doh.gov.ph.
B
74. Baclofen 10 mg Tablet 16.92
75. Beractant 25 mg/mL, 4 mL Vial 10,325.78
76. Betahistine 24 mg Tablet (As Hydrochloride) 54.12
77. Betahistine 8 mg Tablet (As Hydrochloride) 15.77
78. Betamethasone Cream 0.1%, 5 g Tube (As Valerate) 221.67
79. Biperiden 2 mg Tablet (As Hydrochloride) 12.92
80. Bisacodyl 10 mg Suppository 37.69
2017 DPRI | Fifth Edition 5|Page
DPRI (Php)
GENERIC NAME STRENGTH / FORM / VOLUME
(Ceiling Price)
81. Bisacodyl 5 mg Suppository 30.77
82. Bisacodyl 5 mg Tablet 15.38
83. Bleomycin 15 mg Vial (As Sulfate) 2,353.85
84. Budesonide + Formoterol 160 mcg + 4.5 mcg x 60 doses Dry 838.46
Powder Inhaler (As Fumarate
Dihydrate)
85. Budesonide 250 mcg/mL, 2 mL Respiratory 69.23
Solution (Nebule)
86. Bumetanide 1 mg Tablet 22.52
87. Bupivacaine 0.5%, 10 mL Ampule (As 406.68
Hydrochloride)
88. Bupivacaine 0.5%, 10 mL Vial (As Hydrochloride) 325.42
89. Bupivacaine 0.5%, 4 mL (spinal) with 8% Dextrose 457.69
Ampule (As Hydrochloride)
90. Bupivacaine 0.5%, 5 mL Ampule (As 615.38
Hydrochloride)
91. Butamirate 50 mg MR Tablet (As Citrate) 14.22
92. Butorphanol 2 mg/mL, 1 mL Vial (As Tartrate) 436.22
C
93. Calcium Carbonate + Cholecalciferol (Vit. 1.25 g (equiv. to 500 mg elemental 6.73
D3) calcium) + 250 IU Tablet
94. Calcium Carbonate + Cholecalciferol (Vit. 600 mg elementa Ca + 400 IU Vit. D3 6.33
D3) Tablet
95. Calcium Carbonate 500 mg Tablet 5.12
96. Calcium Carbonate 600 mg Tablet 6.15
97. Calcium Folinate (Leucovorin Calcium) 10 mg/mL, 5 mL Ampule 488.46
98. Calcium Folinate (Leucovorin Calcium) 10 mg/mL, 5 mL Vial 280.19
99. Calcium Folinate (Leucovorin Calcium) 50 mg powder Vial 213.65
100. Calcium Gluconate 10%, 10 mL Ampule 76.96
101. Calcium Gluconate 10%, 10 mL Vial 68.88
102. Candesartan 16 mg Tablet (As Cilexetil) 25.27
103. Candesartan 8 mg Tablet (As Cilexetil) 14.62
104. Capecitabine 500 mg Tablet 84.20
105. Captopril 25 mg Tablet 3.85
106. Carbamazepine 200 mg Tablet 5.00
107. Carboplatin 10 mg/mL, 15 mL Vial 918.06
108. Carboplatin 10 mg/mL, 45 mL Vial 3,088.00
109. Carvedilol 25 mg Tablet 14.19
110. Carvedilol 6.25 mg Tablet 8.46
111. Cefadroxil 125 mg/5 mL, 60 mL Syrup (As 146.54
Monohydrate)
112. Cefadroxil 250 mg/5 mL, 60 mL Suspension (As 87.69
Monohydrate)
113. Cefadroxil 500 mg Capsule 10.77
114. Cefalexin 100 mg/mL, 15 mL Drops (As 34.62
Monohydrate)
115. Cefalexin 125 mg/5 mL, 60 mL Bottle (As 46.15
Monohydrate)
116. Cefalexin 250 mg Capsule (As Monohydrate) 3.85
2017 DPRI | Fifth Edition 6|Page
DPRI (Php)
GENERIC NAME STRENGTH / FORM / VOLUME
(Ceiling Price)
117. Cefalexin 250 mg/5 mL, 60 mL Bottle (As 61.54
Monohydrate)
118. Cefalexin 500 mg Capsule (As Monohydrate) 10.02
119. Cefazolin 1 g Vial (As Sodium Salt) 125.50
120. Cefazolin 500 mg Vial (As Sodium Salt) 214.72
121. Cefepime 1 g Vial (As Hydrochloride) 1,486.92
122. Cefepime 2 g Vial (As Hydrochloride) 3,020.67
123. Cefepime 500 mg Vial (As Hydrochloride) 864.96
124. Cefixime 100 mg Capsule (As Trihydrate) 68.46
125. Cefixime 100 mg/5 mL, 30 mL Suspension 450.35
126. Cefixime 100 mg/5 mL, 60 mL Suspension 515.08
127. Cefixime 20 mg/mL, 10 mL Suspension 192.31
128. Cefixime 200 mg Capsule (As Trihydrate) 31.23
129. Cefotaxime 1 g Vial (As Sodium Salt) 224.23
130. Cefotaxime 500 mg Vial (As Sodium Salt) 740.77
131. Cefoxitin 1 g Vial (As Sodium Salt) 814.87
132. Ceftazidime 1 g Vial (As Sodium Salt) 338.46
133. Ceftazidime 500 mg Vial (As Pentahydrate) 651.94
134. Ceftriaxone 1 g + 10 mL diluent Vial (As 576.92
Disodium/Sodium Salt)
135. Ceftriaxone 500 mg + 5 mL diluent Vial (As 566.15
Disodium/Sodium Salt)
136. Cefuroxime 1.5 g Vial 371.15
137. Cefuroxime 125 mg/5 mL, 50 mL Suspension (As 180.77
Axetil)
138. Cefuroxime 125 mg/5 mL, 70 mL Suspension (As 238.46
Axetil)
139. Cefuroxime 250 mg Vial 266.04
140. Cefuroxime 250 mg/5 mL, 60 mL Suspension 238.46
141. Cefuroxime 500 mg Tablet (As Axetil) 45.69
142. Cefuroxime 750 mg Vial 292.31
143. Celecoxib 100 mg Capsule 15.19
144. Celecoxib 200 mg Capsule 19.23
145. Celecoxib 400 mg Capsule 34.46
146. Cetirizine 1 mg/mL, 30 mL Bottle (As 113.85
Dihydrochloride)
147. Cetirizine 1 mg/mL, 60 mL Bottle (As 188.63
Dihydrochloride)
148. Cetirizine 10 mg Tablet (As Dihydrochloride) 16.71
149. Cetirizine 10 mg/mL, 10 mL Oral Drops (As 121.54
Dihydrochloride)
150. Chloramphenicol 1 g Vial (As Sodium Succinate) 50.00
151. Chloramphenicol 125 mg/5 mL, 60 mL Suspension (As 57.69
Palmitate)
152. Chloramphenicol 500 mg Capsule (As Palmitate) 4.62
153. Chlorphenamine (Chlorpheniramine) 10 mg/mL,1 mL Ampule (As Maleate) 31.15
154. Chlorphenamine (Chlorpheniramine) 4 mg Tablet (As Maleate) 1.00
155. Chlorpromazine 100 mg Tablet (As Hydrochloride) 6.54